TSVT logo

2seventy bio (TSVT) Company Overview

Profile

Full Name:

2seventy bio, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

November 3, 2021

Indexes:

Not included

Description:

2seventy bio is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. They use advanced technologies to create personalized treatments, aiming to improve patient outcomes and quality of life. Their work combines science and compassion to address unmet medical needs.

Key Details

Price

$2.43

Annual Revenue

$100.39 M(+9.72% YoY)

Annual EPS

-$4.42(+38.01% YoY)

Annual ROE

-76.91%

Beta

1.71

Events Calendar

Earnings

Next earnings date:

Mar 5, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 5, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jul 29, 24 Morgan Stanley
Equal-Weight
Jun 27, 24 Wedbush
Neutral
May 9, 24 Canaccord Genuity
Buy
Apr 8, 24 Citigroup
Buy
Mar 18, 24 Wedbush
Neutral
Jan 31, 24 TD Cowen
Market Perform
Jan 31, 24 Leerink Partners
Outperform
Nov 20, 23 Wedbush
Neutral
Oct 30, 23 Leerink Partners
Market Perform
Oct 12, 23 Citigroup
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's What You Should Know
2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's What You Should Know
2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's What You Should Know
TSVT
zacks.comDecember 4, 2024

2seventy bio, Inc. (TSVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
TSVT
accesswire.comNovember 16, 2024

NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
TSVT
accesswire.comNovember 14, 2024

NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
TSVT
accesswire.comNovember 12, 2024

NEW YORK CITY, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call Transcript
2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call Transcript
2seventy bio, Inc. (TSVT) Q3 2024 Earnings Call Transcript
TSVT
seekingalpha.comNovember 12, 2024

2seventy bio, Inc. (NASDAQ:TSVT ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Morgan Shields – Corporate Communications Chip Baird – Chief Executive Officer Vicki Eatwell – Chief Financial Officer Conference Call Participants Samantha Semenkow – Citi Daina Graybosch – Leerink Partners Operator Good day and thank you for standing by. Welcome to the 2seventy bio Third Quarter 2024 Earnings Conference Call.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
TSVT
prnewswire.comNovember 10, 2024

NEW YORK , Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
TSVT
prnewswire.comNovember 2, 2024

NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
TSVT
accesswire.comOctober 31, 2024

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
TSVT
accesswire.comOctober 27, 2024

NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
TSVT
accesswire.comOctober 19, 2024

NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

FAQ

  • What is the ticker symbol for 2seventy bio?
  • Does 2seventy bio pay dividends?
  • What sector is 2seventy bio in?
  • What industry is 2seventy bio in?
  • What country is 2seventy bio based in?
  • When did 2seventy bio go public?
  • Is 2seventy bio in the S&P 500?
  • Is 2seventy bio in the NASDAQ 100?
  • Is 2seventy bio in the Dow Jones?
  • When was 2seventy bio's last earnings report?
  • When does 2seventy bio report earnings?
  • Should I buy 2seventy bio stock now?

What is the ticker symbol for 2seventy bio?

The ticker symbol for 2seventy bio is NASDAQ:TSVT

Does 2seventy bio pay dividends?

No, 2seventy bio does not pay dividends

What sector is 2seventy bio in?

2seventy bio is in the Healthcare sector

What industry is 2seventy bio in?

2seventy bio is in the Biotechnology industry

What country is 2seventy bio based in?

2seventy bio is headquartered in United States

When did 2seventy bio go public?

2seventy bio's initial public offering (IPO) was on November 3, 2021

Is 2seventy bio in the S&P 500?

No, 2seventy bio is not included in the S&P 500 index

Is 2seventy bio in the NASDAQ 100?

No, 2seventy bio is not included in the NASDAQ 100 index

Is 2seventy bio in the Dow Jones?

No, 2seventy bio is not included in the Dow Jones index

When was 2seventy bio's last earnings report?

2seventy bio's most recent earnings report was on Nov 12, 2024

When does 2seventy bio report earnings?

The next expected earnings date for 2seventy bio is Mar 5, 2025

Should I buy 2seventy bio stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions